A late-night announcement on August 19 from JUNSHI BIO (688180.SH) brought the curtain down on a two-month reduction campaign by major shareholder Shanghai Tanying Investment Partnership (Limited Partnership). Between June 8 and August 19, Shanghai Tanying offloaded 20.5337 million A-shares through block trades, representing 2% of the company's total share capital, with total proceeds reaching approximately 707 million yuan.
The precision of this reduction was remarkable. Shanghai Tanying had originally planned to sell no more than 20.5338 million shares, yet the actual figure of 20.5337 million shares fell just 97 shares short of the planned cap — effectively hugging the regulatory ceiling throughout the entire selloff. Such meticulous execution is rarely seen in major shareholder reductions on the A-share market, underscoring the firmness of their exit intent.
The selling price ranged from 28.73 yuan to 39.87 yuan per share, a spread exceeding 38%. Based on average estimates, the average transaction price for this reduction was approximately 34.43 yuan per share. Notably, JUNSHI BIO's share price fluctuated significantly during the reduction period, with the gap between the highest and lowest prices exceeding 11 yuan. Shanghai Tanying opted for staggered selling at various price points, reflecting a degree of market-timing strategy.
Following the reduction, Shanghai Tanying's stake fell from 5.79% to 3.79%, formally exiting the "5% club" of major shareholders. This status change carries significant implications: should the firm continue selling in the future, it will no longer be bound by the strict pre-disclosure rules applicable to shareholders holding 5% or more, granting greater operational flexibility. Market analysts suggest that this precise "downshift" below the 5% threshold may be paving the way for further reductions down the line.
Regarding the rationale for the reduction, JUNSHI BIO's announcement cited "fund term maturity and liquidity arrangements" as the reason. While this phrasing is common among PE/VC-backed shareholders, it invites scrutiny given the company's current operational context. As a representative player in China's innovative drug sector, JUNSHI BIO has maintained substantial R&D investment, with commercialization progress closely watched by the market. The timing of this large-scale cash-out inevitably raises concerns about the company's outlook. However, as a financial investor, Shanghai Tanying's exit likely reflects the fund's own lifecycle management needs rather than a direct repudiation of the company's fundamentals.
The 707 million yuan realized from this selloff represents a considerable sum among STAR Market major shareholder reductions this year. In the near term, the large-scale divestment may exert downward pressure on JUNSHI BIO's share price; however, from a medium-to-long-term perspective, the orderly exit of financial investors could actually contribute to optimizing the shareholder structure and enhancing liquidity. The pivotal question remains: will Shanghai Tanying continue selling after dropping to 3.79%? Should the firm opt for a complete exit, the remaining 38.9256 million shares would still pose significant selling pressure on the market. Investors would be wise to monitor subsequent disclosures closely.
As competition intensifies across the innovative drug sector, whether JUNSHI BIO can reward investor patience with solid performance will ultimately underpin its share price. Whether the major shareholder's retreat stems from unavoidable fund maturity constraints or signals a vote of no confidence, only time will tell.